Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients

Makino, Hisashi; Okada, Sadanori; Nagumo, Ayako; Sugisawa, Takako; Miyamoto, Yoshihiro; Kishimoto, Ichiro; Akie, Taura K.; Soma, Toshihiro; Taguchi, Akihiko; Yoshimasa, Yasunao

doi:10.1016/j.diabres.2008.05.012

Cited by 26 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CD34 + BM-CPCs frequency in DM patients with HbA1c > 7% was significantly reduced compared to DM patients with HbA1c < 7%. Recent studies have shown that the PPARϒ agonist pioglitazone treatment increases the number and function of BM-CPCs in type 2 DM patients with coronary artery disease [46,47]. Improved levels of HbA1c by pharmacological therapy may lead to an increase of BM-CPCs frequency and functional activity and thereby may enhance the vascular regeneration in IHD patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

Bozdağ-Turan

Turan

et al. 2011

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundBone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease are impaired with respect to number and mobilization. However, it is unknown whether the mobilization of BM-CPCs depends on the number of diseased coronary arteries. Therefore, in our study, we analysed the correlation between the diseased coronary arteries and the frequency of CD34/45+ BM-CPCs in peripheral blood (PB) in patients with ischemic heart disease (IHD).MethodsThe frequency of CD34/45+ BM-CPCs was measured by flow cytometry in 120 patients with coronary 1 vessel (IHD1, n = 40), coronary 2 vessel (IHD2, n = 40), coronary 3 vessel disease (IHD3, n = 40) and in a control group of healthy subjects (n = 40). There was no significant difference of the total number of cardiovascular risk factors between IHD groups, beside diabetes mellitus (DM), which was significantly higher in IHD3 group compared to IHD2 and IHD1 groups.ResultsThe frequency of CD34/45+ BM-CPCs was significantly reduced in patients with IHD compared to the control group (CD34/45+; p < 0.001). The frequency of BM-CPCs was impaired in patients with IHD3 compared to IHD1 (CD34/45+; p < 0.001) and to IHD2 (CD34/45+; p = 0.001). But there was no significant difference in frequency of BM-CPCs between the patients with IHD2 and IHD1 (CD34/45+; p = 0.28). In a subgroup we observed a significant negative correlation between levels of hemoglobin AIc (HbAIc) and the frequency of BM-CPCs (CD34/45+; p < 0.001, r = -0.8).ConclusionsThe frequency of CD34/45+ BM-CPCs in PB is impaired in patients with IHD. This impairment may augment with an increased number of diseased coronary arteries. Moreover, the frequency of CD34/45+ BM-CPCs in ischemic tissue is further impaired by diabetes in patients with IHD.

show abstract

Section: Discussionmentioning

confidence: 99%

Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

Bozdağ-Turan

Turan

et al. 2011

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…Pioglitazone, a TZD, attenuates AngII-induced cellular senescence and oxidative stress in endothelial cells in vitro [57]. Pioglitazone treatment also increases the number of circulating EPCs in type 2 diabetics and non-diabetic patients with CAD [58,59]. As telmisartan causes AT 1 receptor blockade and PPAR activation, it might be expected to improve vascular function and promote neovascularization via the proliferation of EPCs in ischemic tissue in the clinical setting.…”

Section: The Ppar Dependent Effects Of Arbmentioning

confidence: 95%

The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells

Matsuura¹,

Hagiwara²

2011

CVP

View full text Add to dashboard Cite

Angiotensin II regulates blood pressure and contributes to endothelial dysfunction and the progression of atherosclerosis. Bone marrow-derived endothelial progenitor cells (EPCs) in peripheral blood contribute to postnatal vessel repair and neovascularization. Impaired EPC function in patients with hypertension and diabetes inhibits the endogenous repair of vascular lesions and leads to the progression of atherosclerosis. The number of EPCs in peripheral blood is inversely correlated with mortality and the occurrence of cardiovascular events. Angiotensin II-mediated signaling is implicated in oxidative stress, inflammation and insulin resistance, factors that cause EPC dysfunction. Blockade of the angiotensin II type 1 receptor may therefore present a new therapeutic target for enhancing EPC function.

show abstract

“…In turn, reduced EPC number has been related to the degree of impairment of fl ow-mediated vasodilation in type 2 diabetes ( 101 ). In experimental animal models and clinical studies, TZD drugs have been shown to stimulate production of EPCs and promote endothelial repair after vascular injury (102)(103)(104)(105)(106).…”

Section: Endothelial Function Vascular Smooth Muscle Cell Proliferatmentioning

confidence: 99%

PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

Huang

Greyson

Schwartz

2012

Journal of Lipid Research

View full text Add to dashboard Cite

Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients

Cited by 26 publications

References 21 publications

Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells

PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty

Contact Info

Product

Resources

About